Network Analysis Identifies an HSP90-Central Hub Susceptible in Ovarian Cancer
暂无分享,去创建一个
Hanqing Liu | Erica A. Golemis | Denise C. Connolly | Samuel Litwin | Ilya G. Serebriiskii | S. Litwin | D. Proia | E. Golemis | I. Astsaturov | I. Serebriiskii | Lainie P. Martin | Hanqing Liu | D. Connolly | Igor Astsaturov | S. O’Brien | F. Xiao | Fang Xiao | Shane W. O'Brien | Marisa A. Maglaty | David A. Proia | Lainie P Martin
[1] Domenico Coppola,et al. Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] G. Nolan,et al. Rapid Production of Retroviruses for Efficient Gene Delivery to Mammalian Cells Using 293T Cell–Based Systems , 1999, Current protocols in immunology.
[3] A. Godwin,et al. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. , 2011, Gynecologic oncology.
[4] Karthik Devarajan,et al. Synthetic Lethal Screen of an EGFR-Centered Network to Improve Targeted Therapies , 2010, Science Signaling.
[5] R. Makuch,et al. cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer. , 1979, Cancer treatment reports.
[6] P. van Damme,et al. Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma. , 1994, Journal of clinical pathology.
[7] P. Quesenberry,et al. Coexpression of oncostatin M and its receptors and evidence for STAT3 activation in human ovarian carcinomas. , 2002, Cytokine.
[8] Jean-François Ethier,et al. Reproductive Biology and Endocrinology Open Access Animal Models of Ovarian Cancer , 2022 .
[9] Kathleen R. Cho,et al. Ovarian cancer update: lessons from morphology, molecules, and mice. , 2009, Archives of pathology & laboratory medicine.
[10] C. Szczylik,et al. Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study. , 2011, Gynecologic oncology.
[11] I. Shih,et al. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. , 2011, Human pathology.
[12] I. Jacobs,et al. Genetic intra‐tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours , 2007, The Journal of pathology.
[13] M. Birrer,et al. Genomic analysis of epithelial ovarian cancer , 2008, Cell Research.
[14] Alison Stopeck,et al. HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab , 2011, Clinical Cancer Research.
[15] G. Mills,et al. Targeting the Epidermal Growth Factor Receptor in Epithelial Ovarian Cancer: Current Knowledge and Future Challenges , 2009, Journal of oncology.
[16] D. Proia,et al. Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy , 2011, Molecular Cancer Therapeutics.
[17] J. Foekens,et al. Receptors for hormones and growth factors and (ONCO)‐gene amplification in human ovarian cancer , 1992, International journal of cancer.
[18] G. Mills,et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells , 2006, Molecular Cancer Therapeutics.
[19] David S. Wishart,et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..
[20] Trey Ideker,et al. Functional Maps of Protein Complexes from Quantitative Genetic Interaction Data , 2008, PLoS Comput. Biol..
[21] Liz Y. Han,et al. Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. , 2006, Cancer research.
[22] E. Rowinsky,et al. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms , 1990, Annals of internal medicine.
[23] A. Oza,et al. A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149). , 2010, Gynecologic oncology.
[24] Anil K Sood,et al. Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[25] A. Oza,et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. , 2008, Gynecologic oncology.
[26] I. Fidler,et al. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. , 2005, Cancer research.
[27] T. Chou,et al. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.
[28] A. Krishnan,et al. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study , 2011, British journal of haematology.
[29] Ting-Chao Chou,et al. Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.
[30] M. Meyerson,et al. Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.
[31] Jiayuh Lin,et al. Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells. , 2000, Gynecologic oncology.
[32] Bin Liu,et al. Michigan Molecular Interactions (MiMI): putting the jigsaw puzzle together , 2006, Nucleic Acids Res..
[33] Weiwei Zhong,et al. Genome-Wide Prediction of C. elegans Genetic Interactions , 2006, Science.
[34] A. Sood,et al. Overexpression of the Centrosomal Protein Aurora-A Kinase is Associated with Poor Prognosis in Epithelial Ovarian Cancer Patients , 2007, Clinical Cancer Research.
[35] J. Foekens,et al. Ki‐67 staining in benign, borderline, malignant primary and metastatic ovarian tumors: Correlation with steroid receptors, epidermal‐growth‐factor receptor and cathepsin D , 1994, International journal of cancer.
[36] Pablo C. Echeverría,et al. An Interaction Network Predicted from Public Data as a Discovery Tool: Application to the Hsp90 Molecular Chaperone Machine , 2011, PloS one.
[37] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[38] J. Deloia,et al. Centrosome abnormalities in ovarian cancer , 2005, International journal of cancer.
[39] Yiling Lu,et al. Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. , 2010, Cancer research.
[40] Wenjun Cheng,et al. Activated Signal Transducer and Activator of Transcription (STAT) 3 , 2004, Cancer Research.
[41] D. Proia,et al. Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models , 2012, Investigational New Drugs.
[42] J. Thigpen,et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] Michael Peyton,et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells , 2007, Nature.
[44] R. Edwards,et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study , 2004, International Journal of Gynecologic Cancer.
[45] P. Workman,et al. Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino , 17-Demethoxygeldanamycin in Human Ovarian Cancer , 2005 .
[46] Gabriela Chiosis,et al. Discovery and development of heat shock protein 90 inhibitors. , 2009, Bioorganic & medicinal chemistry.
[47] D. Connolly,et al. Xenograft and Transgenic Mouse Models of Epithelial Ovarian Cancer and Non Invasive Imaging Modalities to Monitor Ovarian Tumor Growth In situ -Applications in Evaluating Novel Therapeutic Agents. , 2009, Current protocols in pharmacology.
[48] F. Hodi,et al. Activity of the Heat Shock Protein 90 Inhibitor Ganetespib in Melanoma , 2013, PloS one.
[49] A. Godwin,et al. Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. , 2012, Gynecologic oncology.
[50] D. Connolly,et al. Xenograft and Transgenic Mouse Models of Epithelial Ovarian Cancer and Non‐Invasive Imaging Modalities to Monitor Ovarian Tumor Growth In Situ: Applications in Evaluating Novel Therapeutic Agents , 2009, Current protocols in pharmacology.
[51] S. Keir,et al. Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program , 2012, Pediatric blood & cancer.
[52] I. Benjamin,et al. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[53] D. Proia,et al. Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT Signaling , 2011, PloS one.
[54] A. Sood,et al. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. , 2012, Gynecologic oncology.
[55] E. Petricoin,et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] L. Ellis,et al. An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients , 2004, Oncogene.
[57] S. Kaye,et al. New Strategies in the Treatment of Ovarian Cancer: Current Clinical Perspectives and Future Potential , 2013, Clinical Cancer Research.
[58] Helen X. Chen,et al. Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. , 2010, Gynecologic oncology.
[59] Paul Workman,et al. Hsp90 Molecular Chaperone Inhibitors: Are We There Yet? , 2012, Clinical Cancer Research.
[60] Andrew K Godwin,et al. A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. , 2012, Gynecologic oncology.
[61] S. Keir,et al. Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program , 2013, Pediatric blood & cancer.
[62] A. Godwin,et al. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. , 2011, Gynecologic oncology.
[63] C. Hudis,et al. A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors , 2012, Clinical Cancer Research.
[64] A. Shaw,et al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. , 2013, Cancer discovery.
[65] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[66] Christopher C. Taylor,et al. Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line. , 2003, Biochemical and biophysical research communications.
[67] M. Gore. First line Chemotherapy for Epithelial Ovarian Cancer , 2001 .
[68] S. Lindquist,et al. HSP90 at the hub of protein homeostasis: emerging mechanistic insights , 2010, Nature Reviews Molecular Cell Biology.
[69] Trey Ideker,et al. Cytoscape 2.8: new features for data integration and network visualization , 2010, Bioinform..
[70] Stephen J. Williams,et al. Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer , 2007, Cancer biology & therapy.
[71] Paul Talalay,et al. Analysis of combined drug effects: a new look at a very old problem , 1983 .
[72] B. Vanderhyden,et al. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] A. Godwin,et al. Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion , 2014, Oncogene.
[74] A. Oberg,et al. A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma. , 2012, Gynecologic oncology.
[75] D. Ettinger,et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. , 1989 .
[76] W. Ou,et al. Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation , 2011, Molecular Cancer.
[77] Damian Szklarczyk,et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored , 2010, Nucleic Acids Res..
[78] C. Gilks,et al. Ovarian carcinoma pathology and genetics: recent advances. , 2009, Human pathology.
[79] Barbara C Vanderhyden,et al. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. , 2003, Cancer research.
[80] B. Krishnan,et al. Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT , 2006, Molecular Cancer Therapeutics.
[81] B. Davidson,et al. Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions. , 2012, Human pathology.
[82] P. Workman. Altered states: selectively drugging the Hsp90 cancer chaperone. , 2004, Trends in molecular medicine.
[83] I. Konishi,et al. Immunohistochemical localization of c-erbB-2 protein and epidermal growth factor receptor in normal surface epithelium, surface inclusion cysts, and common epithelial tumours of the ovary , 2005, Virchows Archiv A.